| Imara Dives Into Coronavirus-Churned Financial Waters With a $75M IPO | Frank Vinluan | 03/12/20 | Boston |
| Kymera Closes $102M Round to Bring Protein-Busting Drugs to the Clinic | Frank Vinluan | 03/12/20 | Boston |
| Xcelerating Life Sciences San Diego Will Be Delivered Digitally | Editors | 03/11/20 | National |
| With Bristol and Otsuka on Board, LSP Raises $620M EU Life Sciences Fund | Dan Stanton | 03/11/20 | Europe |
| Silverback Therapeutics Adds $79M to Test HER2+ Tumor-Targeting Drug | Sarah de Crescenzo | 03/11/20 | Seattle |
| Acceleron Drops Drug for Rare Muscle Disease After Mixed Phase 2 Data | Frank Vinluan | 03/10/20 | Boston |
| Kala to Take Another Shot at FDA Approval With New Dry Eye Drug Data | Sarah de Crescenzo | 03/09/20 | Boston |
| Cushing’s Disease Drug That Novartis Sold to Recordati Nabs FDA Nod | Frank Vinluan | 03/09/20 | Europe |
| Zentalis Leads a Trio of Biotechs Charting a Course for Wall Street | Frank Vinluan | 03/09/20 | New York |
| Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More | Sarah de Crescenzo | 03/06/20 | National |
| Roche Trial of Ionis Huntington’s Disease Drug Halted After Side Effects | Sarah de Crescenzo | 03/05/20 | San Diego |
| Culture Biosciences Adds $15M for New Software, Bioreactor Expansion | Gareth Macdonald | 03/05/20 | San Francisco |
| Melinta’s Chapter 11 Auction Draws No Bids, Deerfield to Get Assets | Frank Vinluan | 03/04/20 | New York |
| Amunix Raises $73M to Bring Safer T Cell Engagers to Solid Tumors | Sarah de Crescenzo | 03/04/20 | San Francisco |
| Court Rules More Trial Data Must Be Posted On ClinicalTrials.gov | Brenda Sandburg | 03/04/20 | National |
| Novartis Leads $100M Round for Fibrosis-Focused Pliant Therapeutics | Frank Vinluan | 03/03/20 | San Francisco |
| Sanofi Wins FDA Nod for Combo Therapy in Multiple Myeloma | Sarah de Crescenzo | 03/03/20 | National |
| National Xconomy Awards Now Accepting Nominations for the Best in Biotech | Editors | 03/03/20 | National |
| Gilead Boosts Cancer Drug Pipeline With $4.9B Deal for Forty Seven | Frank Vinluan | 03/02/20 | San Francisco |
| ORIC Pharma Plans IPO to Test Therapies for Drug-Resistant Cancers | Sarah de Crescenzo | 03/02/20 | San Francisco |
| Xilio Unveils New Name, $100M to Bring Targeted Cancer Drugs to Clinic | Frank Vinluan | 03/02/20 | Boston |
| Biogen, Sangamo Ink Neuro Deal for New “Gene Regulation” Therapies | Sarah de Crescenzo | 02/28/20 | National |
| Bio Roundup: COVID-19 Trials, Esperion’s Approvals, NASH News & More | Frank Vinluan | 02/28/20 | National |
| Passage Bio’s IPO Raises $216M to Fund Gene Therapy Studies | Sarah de Crescenzo | 02/28/20 | National |
| Biohaven’s Migraine Pill Is the Latest CGRP Drug to Win the FDA’s OK | Frank Vinluan | 02/27/20 | New York |
| Gilead, Moderna Candidates Ramp Up Coronavirus Drug, Vaccine Testing | Sarah de Crescenzo | 02/27/20 | National |
| Esperion’s Combo Pill for Lowering Cholesterol Levels Wins FDA Nod | Frank Vinluan | 02/26/20 | Detroit Ann Arbor |
| Takeda Bases PvP Biologics Buyout on Promising Early Celiac Drug Data | Sarah de Crescenzo | 02/26/20 | San Diego |
| With Foamix Merger Weeks Away, Menlo Itching Drug Fails a Phase 2 Test | Frank Vinluan | 02/26/20 | San Francisco |
| Bicycle Therapeutics Lands $30M From Genentech in New Cancer R&D Pact | Frank Vinluan | 02/25/20 | Boston |
